Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours Β· Estimated delivery Aug 16 - Aug 21
Roughly 18 million Americans were using GLP-1 medications for weight loss by 2024 , with another 30-35% expressing interest
Its becoming a multi-disease cardiometabolic platform spanning: Cardiovascular disease Obstructive sleep apnoea (OSA) MASH Chronic kidney disease And importantly: Oral obesity therapy is now real not theoretical But the category is already splitting: Peptide oral (with friction) Small-molecule oral (lower friction) That distinction will matter more than pill vs injection Peptide oral (with friction) Small-molecule oral (lower friction) That distinction will matter more than pill vs injection The Most Misunderstood Opportunity: OSA OSA has gone from interesting to commercially meaningful fast Tirzepatide is now the first approved drug for OSA in obesity Phase 3 data showed:~2529 events/hour reduction in AHI Up to ~50% reaching disease-resolution criteria Thats real
Cholesterol: 23mg
This can manifest as pins and needles sensations, especially upon waking
